Page 4 - CJO_SP18

IINTRODUCING

XIIDRA

XIIDRA is indicated for the treatment of the
signs and symptoms of Dry Eye Disease.

*
There’s a new prescription eye drop for Xiidra is the first and only molecule in its class
patients with Dry Eye Disease. Lifitegrast is a lymphocyte function associated
antigen-1 (LFA-1) antagonist.
Xiidra is a sterile, preservative-free solution.
®
It comes packaged in 60 single-use containers For more information:
and is used twice daily in each eye, about Consult the complete Product Monograph at
12 hours apart. 1 http://www.shirecanada.com/pm/en/Xiidra.pdf for
further information on contraindications, warnings,
precautions, adverse reactions, and dosage and
administration. The Product Monograph is also
available at: 1-800-268-2772

Stay tuned. Product available soon.

Reference: 1. Xiidra Product Monograph. Shire Pharma Canada ULC, December 2017.
*Comparative clinical significance has not been established.

® Xiidra and the Xiidra logo are trademarks or registered trademarks of SARcode Bioscience Inc.,
a wholly-owned, indirect subsidiary of Shire plc. SHIRE and the Shire logo are trademarks or
registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates.
© 2018 Shire Pharma Canada ULC. All rights reserved.
PRMCDA/CA//0360

37529_CJO_SP18 February 20, 2018 10:55 AM APPROVAL: ___________________ DATE: ___________________